Kai Kupferschmidt

2 papers in the library · 15 citations · publishing 2024

Papers

Sort Most recent Most cited

Science August 16, 2024 Kai Kupferschmidt 12 citations

Lykos's failure to win FDA approval for PTSD therapy may accelerate a strategic shift among its competitors.

DOI: 10.1126/science.ads4470 Full text Psychedelic medicine Mental health treatments Pharmaceutical research Drug development +1

Science June 14, 2024 Kai Kupferschmidt 3 citations

Reeling from negative vote on MDMA-assisted PTSD therapy, researchers seek lessons for future studies.

DOI: 10.1126/science.adr0286 Full text Psychedelic-medicine MDMA-Therapy Clinical-trials Drug-regulation +1